Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Why would PPS not be higher than 35.00 on good data ? If the data is good that means almost 100% chance of FDA approval since the endpoint for approval is basic...10% better effects. Its a pretty straight forward trial.It's not complicated trying to figure out if the data is good then it will be approvedWith 60 years without a new H&N drug and you even have the president Trump stating we need new cancer drugs its hard to for FDA not to approve if endpoint was met. It will be hard for shorts to spin the data news if its good.
I said when FDA approved...you need to listen better....why do you only give 1 billion valuation if FDA approved ?, sounds like you don't know how to valuate properly.It will become SOC even the President is pushing for new cancer drugs. If FDA approved they will have 5 billion to 10 billion in revenue annually,even the CEO said that would be a fair valuation. and most Pharma companies with drugs have a multiple of 4x sales , so how the hell you going to say the company would only be 1 billion is a fair valuation if FDA approved ? Jeez you really need to learn how to valuate properly.
If not then how do you come to future valuations ? and determine risk reward ? I guess I Invest differently but I have to have some sort of idea what the future will bring. I am even prepared for 1.00 but the odds of that now have changed over the last month with this stock.
sab63090 I guess Geert eats "wild Mushrooms too"...since he thinks this company valuation will be worth 8 - 10 billion.
Variables,,,the only one you need is that its better than 10% on data. Cmon go out on limb and take a guess.... there will be bids showing up for MM's to read while its halted to help them set an open price to start trading again . I think somewhere between 60.00 - 80.00....then move up over 100.00 the following week. GLTA
What PPS do you think it starts trading again after the Halt ?
It's hard to put a valuation on what the PPS should be without the data right now but yes the stock should be higher now that the first half of 2019 is done and no 298 event. I would like to see the stock move up to 15.00 range before the big news hits. GLTA
CVM
1 billion ? your valuation estimate is a joke lol, try higher than that. At least 5 billion + on good P3 Multikine data.
CVM
First half of 2019 officially done and No 298 event. I'm expecting a strong move above 10.00 in July.
CVM
CEO Meeting with the FDA mid summer for IND .
Very Nice Article , thankyou for taking the time to write that.
"If Multikine is successful for HNC, then it will be studied for many more types of cancer such as breast and cervical. The market potential is enormous.
We reiterate our $250 per share.
A buyout is always a possibility. Recent buyouts of similar bios have been in the $2B to $12B range, as noted above. Even at $2B, the share price would be about $50 a share...a multi-multi bagger."
CVM Long
You are too afraid to post your trades so we don't really know.
I trade for a living like you. Fact is all CVM shorts are now underwater, what your next move ? to short more and dig yourself a deeper hole or cover ?
Russell 2000 July 1 , and we have Data that should have come already...the 10% endpoint has been reached IMO.
You shorts don't have a leg to stand on.
In at 4.25, check my post history. I post when I buy and sell. Unlike you....you are a non professional.
Yup a sheep that makes money off short traders like you that do not know what the hell you're doing. You have no skill.The squeeze will continue to 12.00..then we wait for data... We smashed you clay turds in VKTX too.
All shorts in this stock are underwater now Clay including you.You got smoked. When Geert drops the data news cover at 100.00.
CVM
"It should be called by the FDA the first Non toxic cancer drug"
Geert / CEO / CVM
Solid performer today, I expect to see 10.00 - 12.00 range this month.
CVM
Bought last week , averaged at 4.25 I can see this going to 50.00 + this year on Multikine FDA approval. Also it will be for other cancers as well so the potential could go to 200.00 PPS.
Trump cutting the red tape to speed up the approval process is perfect time with P3 data coming in Sept.
CVM
Still holding strong, I'm here for the short squeeze or buyout.
VKTX
All the Analysts covering this stock have Targets above 20.00, and Raymond James has 40.00 PT.
VKTX
It should move up to 13.00 fairly quickly once it breaks the key 200mda, Then grind back up to offering price 18.50 and higher into 20's by mid summer when they start their 2b vk2809 trial.If they get a vk5211 partner before that then it will get there on that news alone in 1 days worth of trading except I just don't want Gaps left behind on the chart so I'm hoping for a smooth grind up. JMHO
VKTX
Break the 200dma around 10.80 and we should see a nice rally, my target price is 18.50 where they did the secondary stock offering. GLTA
VKTX
Forget bitcoin, cannabis is the place to go, says US wealth advisor
https://www.cnbc.com/2019/02/22/forget-bitcoin-cannabis-is-the-place-to-go-says-us-wealth-advisor.html?__source=twitter%7Cmain
SVB Leerink upgraded VKTX from Market Perform to Outperform with a 21.00 target is what lifted it. Funny thing it is now close to breaking the 200mda at 10.80 and causing a major short squeeze with 45% of float still short.
VKTX
Getting a nice lift up today ..,, VK2809 .05 mg is the real deal.Will be a blockbuster drug.
VKTX
Cool not even worried about that. The Fundamentals are improving and I think Q2,Q3 and Q4 earnings will surprise you.
VKTX
Been a couple years since I last was in this stock and profited very well. Just took a starter at the close Grabbed a nice chunk at .99 and Will be adding more in the coming days.I can see this going to 4.00 in Q4. GLTA
TRTC
Yes they are nuts, stock is almost trading at almost book value. They are completely discounting VK2809 , 5211, and 0214 as if its worth nothing.
The short squeeze with 40% short will be massive. Raymond James 40.00 target is no joke.
VKTX
I still wish they would have done a 2/3 trial instead of a 2b, Even if they are best in class it will take too long and put them about 3 years behind MDGL.
Not sure why they decided to scrap 5211 from hip fractures but Im very dissapointed with CEO Brian. Lets hope that they have good results testing for Orphan IND with muscle related losses.
Brian is not going to give away the company for peanuts. 12.00 is not even funny.
I would say 6 billion is a fair asking price
VKTX
CymaBay And Viking Therapeutics In NASH, And The Market Assessment
https://seekingalpha.com/article/4245504-cymabay-viking-therapeutics-nash-market-assessment
looks like there is support around 50mda 8.26,when it breaks 10.67 200mda it will fly and should see a shortsqueeze with 41% of float short. I'm still waiting on a Partnership or Buyout PR.
https://stockcharts.com/h-sc/ui?s=VKTX
VKTX
The $35 billion race to cure a silent killer that affects 30 million Americans
https://www.cnbc.com/amp/2018/12/21/the-35-billion-race-for-a-cure-for-a-liver-disease-that-affects-millions.html?__twitter_impression=true
37 % of the float is short, this is setting up for one of the Biggest short squeezes you will ever witness when the next PR comes.
VKTX
Partnership or possible Buyout is next. You have to be in it to win it.
VKTX
When vk2809 Biopsy data comes in it will be much better than MGL3196.
"Madrigal's results come from former NAFLD patients that progressed to NASH, which basically means their livers were already inflamed and sustaining damage."
VKTX
VKTX P2 study had better results than MDGL. 91% of VKTX patients had 30% liver fat reduction while MDGL had only 60% patients with 30% reduction. VKTX has a better drug than MDGL
http://ir.vikingtherapeutics.com/2018-11-12-Viking-Therapeutics-Presents-Results-from-Phase-2-Study-of-VK2809-in-Patients-with-Non-Alcoholic-Fatty-Liver-Disease-NAFLD-and-Elevated-LDL-Cholesterol-in-Oral-Late-Breaker-Presentation-at-The-Liver-Meeting-R-2018
I think Gilead Sci. wants to Buyout VKTX to stay competing in NASH market, 43.00 is a fair amount if you agree with Raymond James analyst.
https://finance.yahoo.com/news/where-gilead-sciences-inc-5-110000545.html